Literature DB >> 16470838

Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence.

Christoph Fiola1, Ben Peeters, Philippe Fournier, Annette Arnold, Mariana Bucur, Volker Schirrmacher.   

Abstract

To investigate tumor-selective viral replication, we compared several tumorigenic human cell lines to nontumorigenic human cells from the blood for the sensitivity to become infected by a recombinant lentogenic strain of Newcastle Disease Virus (NDV) with incorporated transgene EGFP (NDFL-EGFP). Although fluorescence signals in nontumorigenic cells were only weak or missing completely, a massive and long-lasting transgene-expression was observed in all tumor cell lines. The majority of tumor cells (50-95%) could be infected, and viral replication was associated with an increase in the cell surface density of viral antigens. To clarify the underlying mechanism of the observed difference in virus susceptibility we examined the kinetics of interferon-induced antiviral enzymes because NDV is a strong type-I interferon inducer. This analysis revealed several defects of tumor cells in their antiviral defence responses: They showed no response to UV-inactivated NDV, whereas nontumorigenic cells reacted with induction of high-levels of the antiviral enzymes PKR and MxA. Upon coincubation with live NDV, tumor cells showed a delayed response in the increased expression of the antiviral enzymes in comparison with PBMC. In nontumorigenic cells the replication cycle of NDV stopped after the production of positive-strand RNA, while tumor cells continued in the replication cycle and copied viral genomes 10-50 hr after infection. These results can explain the tumor selective replication behavior of this interesting antineoplastic virus. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470838     DOI: 10.1002/ijc.21821

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  56 in total

1.  Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway.

Authors:  Wei-Choong Ch'ng; Noraini Abd-Aziz; Meng-Hua Ong; Eric J Stanbridge; Norazizah Shafee
Journal:  Cell Oncol (Dordr)       Date:  2015-05-01       Impact factor: 6.730

2.  Cell-type-specific innate immune response to oncolytic Newcastle disease virus.

Authors:  Moanaro Biswas; Sandeep R P Kumar; Adria Allen; Wang Yong; Ramadevi Nimmanapalli; Siba K Samal; Subbiah Elankumaran
Journal:  Viral Immunol       Date:  2012-07-18       Impact factor: 2.257

Review 3.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

4.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

5.  Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.

Authors:  Subbiah Elankumaran; Vrushali Chavan; Dan Qiao; Raghunath Shobana; Gopakumar Moorkanat; Moanaro Biswas; Siba K Samal
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

6.  Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.

Authors:  P R A Buijs; C H J van Eijck; L J Hofland; R A M Fouchier; B G van den Hoogen
Journal:  Cancer Gene Ther       Date:  2014-01-03       Impact factor: 5.987

7.  The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo.

Authors:  Muhannad Alkassar; Barbara Gärtner; Klaus Roemer; Friedrich Graesser; Jean Rommelaere; Lars Kaestner; Isabelle Haeckel; Norbert Graf
Journal:  J Neurooncol       Date:  2011-05-24       Impact factor: 4.130

8.  Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.

Authors:  Dmitriy Zamarin; Luis Martínez-Sobrido; Kaitlyn Kelly; Mena Mansour; Gang Sheng; Adam Vigil; Adolfo García-Sastre; Peter Palese; Yuman Fong
Journal:  Mol Ther       Date:  2009-02-10       Impact factor: 11.454

9.  Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus.

Authors:  Sangita Venkataraman; Seshidhar P Reddy; Jackie Loo; Neeraja Idamakanti; Paul L Hallenbeck; Vijay S Reddy
Journal:  Structure       Date:  2008-10-08       Impact factor: 5.006

10.  The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling.

Authors:  Wei-Choong Ch'ng; Eric J Stanbridge; Khatijah Yusoff; Norazizah Shafee
Journal:  J Interferon Cytokine Res       Date:  2013-03-18       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.